cilengitide

Phase 3Peptide

Cilengitide is an experimental cancer drug that was being tested to treat certain brain tumors (glioblastomas) by blocking proteins that help cancer cells attach to blood vessels and grow.[1] cilengitide is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]

cilengitide is one of 509 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

508

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Lung CancerActive, not recruiting

Central Nervous System NeoplasmActive, not recruiting

LymphomaActive, not recruiting

Diffuse Intrinsic Pontine GliomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Kidney DiseaseActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

Central Nervous System NeoplasmPhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Diffuse Intrinsic Pontine GliomaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

cilengitide

EMD Serono

Phase 3

1 2

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 3

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 4

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma Multiforme5 trials

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01122888·41 enrolled

Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene

Unknown status·NNorthern Sydney and Central Coast Area Health Service·Phase 2·NCT01124240·48 enrolled

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00112866·30 enrolled

Show 2 more trials

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00085254·112 enrolled

Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT00093964·81 enrolled

Glioblastoma4 trials

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT01782976

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

Completed· EMD Serono logo

EMD Serono·Phase 3·NCT00689221·545 enrolled

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT00813943·265 enrolled

Show 1 more trial

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00979862·47 enrolled

Patients With Advanced Solid Tumors2 trials

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01276496·13 enrolled

EMD 121974 in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00022113·35 enrolled

Diffuse Intrinsic Pontine Glioma2 trials

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

Terminated·MMartin-Luther-Universität Halle-Wittenberg·Phase 2·NCT01517776·28 enrolled

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

Completed·CCentre Oscar Lambret·Phase 1·NCT01165333·32 enrolled

Glioma2 trials

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

Completed·NNew Approaches to Brain Tumor Therapy Consortium·Phase 1/2·NCT00006093

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00679354·30 enrolled

12 more indications

Metastatic Prostate Cancer1 trial

Cilengitide in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00103337·106 enrolled

Metastatic Melanoma1 trial

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00082875·56 enrolled

Primary Brain Tumor1 trial

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00063973·24 enrolled

Prostate Cancer1 trial

Cilengitide in Treating Patients With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00121238·16 enrolled

Kaposi's sarcoma1 trial

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00006222·30 enrolled

Lung Cancer1 trial

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

Completed·UUniversitätsmedizin Mannheim·Phase 1·NCT00884598·19 enrolled

Renal Impairment1 trial

Pharmacokinetics in Subjects With Renal Impairment

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01504165·32 enrolled

Squamous Cell Carcinoma1 trial

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00705016·184 enrolled

Lymphoma1 trial

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00077155·45 enrolled

Acute Myeloid Leukemia1 trial

Cilengitide in Treating Patients With Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00089388·70 enrolled

Metastatic Cancer1 trial

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Completed·IIndiana University School of Medicine·Phase 1·NCT00004258·40 enrolled

Small Cell Lung Cancer1 trial

Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00842712·232 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for cilengitide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cilengitide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cilengitide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMD Serono company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Integrin Alpha-V/beta-3 Antagonist; Integrin Alpha-V/beta-5 Antagonist[2]
Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: EMD Serono

cilengitide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma Multiforme5 trials

Glioblastoma4 trials

Patients With Advanced Solid Tumors2 trials

Diffuse Intrinsic Pontine Glioma2 trials

Glioma2 trials

Metastatic Prostate Cancer1 trial

Metastatic Melanoma1 trial

Primary Brain Tumor1 trial

Prostate Cancer1 trial

Kaposi's sarcoma1 trial

Lung Cancer1 trial

Renal Impairment1 trial

Squamous Cell Carcinoma1 trial

Lymphoma1 trial

Acute Myeloid Leukemia1 trial

Metastatic Cancer1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News